Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Targeting CCR5 trafficking to inhibit HIV-1 infection.

Boncompain G, Herit F, Tessier S, Lescure A, Del Nery E, Gestraud P, Staropoli I, Fukata Y, Fukata M, Brelot A, Niedergang F, Perez F.

Sci Adv. 2019 Oct 16;5(10):eaax0821. doi: 10.1126/sciadv.aax0821. eCollection 2019 Oct.

2.

CCR5 structural plasticity shapes HIV-1 phenotypic properties.

Colin P, Zhou Z, Staropoli I, Garcia-Perez J, Gasser R, Armani-Tourret M, Benureau Y, Gonzalez N, Jin J, Connell BJ, Raymond S, Delobel P, Izopet J, Lortat-Jacob H, Alcami J, Arenzana-Seisdedos F, Brelot A, Lagane B.

PLoS Pathog. 2018 Dec 6;14(12):e1007432. doi: 10.1371/journal.ppat.1007432. eCollection 2018 Dec.

3.

CCR5 Revisited: How Mechanisms of HIV Entry Govern AIDS Pathogenesis.

Brelot A, Chakrabarti LA.

J Mol Biol. 2018 Aug 17;430(17):2557-2589. doi: 10.1016/j.jmb.2018.06.027. Epub 2018 Jun 19. Review.

PMID:
29932942
4.

CCR5 adopts three homodimeric conformations that control cell surface delivery.

Jin J, Momboisse F, Boncompain G, Koensgen F, Zhou Z, Cordeiro N, Arenzana-Seisdedos F, Perez F, Lagane B, Kellenberger E, Brelot A.

Sci Signal. 2018 May 8;11(529). pii: eaal2869. doi: 10.1126/scisignal.aal2869.

PMID:
29739880
5.

Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.

Jin J, Colin P, Staropoli I, Lima-Fernandes E, Ferret C, Demir A, Rogée S, Hartley O, Randriamampita C, Scott MG, Marullo S, Sauvonnet N, Arenzana-Seisdedos F, Lagane B, Brelot A.

J Biol Chem. 2014 Jul 4;289(27):19042-52. doi: 10.1074/jbc.M114.559831. Epub 2014 May 22.

6.

HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines.

Colin P, Bénureau Y, Staropoli I, Wang Y, Gonzalez N, Alcami J, Hartley O, Brelot A, Arenzana-Seisdedos F, Lagane B.

Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9475-80. doi: 10.1073/pnas.1222205110. Epub 2013 May 21.

7.

Identification of a postendocytic sorting sequence in CCR5.

Delhaye M, Gravot A, Ayinde D, Niedergang F, Alizon M, Brelot A.

Mol Pharmacol. 2007 Dec;72(6):1497-507. Epub 2007 Sep 12.

PMID:
17855654
8.

On the dimerization of CCR5.

Lemay J, Marullo S, Jockers R, Alizon M, Brelot A.

Nat Immunol. 2005 Jun;6(6):535; author reply 535-6. No abstract available.

PMID:
15908929
9.

Identification of the cytoplasmic domains of CXCR4 involved in Jak2 and STAT3 phosphorylation.

Ahr B, Denizot M, Robert-Hebmann V, Brelot A, Biard-Piechaczyk M.

J Biol Chem. 2005 Feb 25;280(8):6692-700. Epub 2004 Dec 22.

10.

The composition of the beta-2 adrenergic receptor oligomer affects its membrane trafficking after ligand-induced endocytosis.

Cao TT, Brelot A, von Zastrow M.

Mol Pharmacol. 2005 Jan;67(1):288-97. Epub 2004 Oct 18.

PMID:
15492118
11.

HIV-1 entry and how to block it.

Brelot A, Alizon M.

AIDS. 2001;15 Suppl 5:S3-11. Review. No abstract available.

PMID:
11816172
12.

Antigenically distinct conformations of CXCR4.

Baribaud F, Edwards TG, Sharron M, Brelot A, Heveker N, Price K, Mortari F, Alizon M, Tsang M, Doms RW.

J Virol. 2001 Oct;75(19):8957-67.

13.
14.

Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay.

Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, Alizon M, Scarlatti G, Clavel F, Mammano F.

J Virol. 2001 Jan;75(1):251-9.

15.
16.

Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses.

Brelot A, Heveker N, Adema K, Hosie MJ, Willett B, Alizon M.

J Virol. 1999 Apr;73(4):2576-86.

17.

The second extracellular loop of CXCR4 is involved in CD4-independent entry of human immunodeficiency virus type 2.

Reeves JD, Heveker N, Brelot A, Alizon M, Clapham PR, Picard L.

J Gen Virol. 1998 Jul;79 ( Pt 7):1793-9.

PMID:
9680144
18.

The second extracellular loop of CXCR4 determines its function as a receptor for feline immunodeficiency virus.

Willett BJ, Adema K, Heveker N, Brelot A, Picard L, Alizon M, Turner JD, Hoxie JA, Peiper S, Neil JC, Hosie MJ.

J Virol. 1998 Aug;72(8):6475-81. Erratum in: J Virol 1998 Oct;72(10):8460.

19.

Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100.

Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, Alizon M.

J Virol. 1998 Aug;72(8):6381-8.

20.

HIV-1 gp120 induces an association between CD4 and the chemokine receptor CXCR4.

Ugolini S, Moulard M, Mondor I, Barois N, Demandolx D, Hoxie J, Brelot A, Alizon M, Davoust J, Sattentau QJ.

J Immunol. 1997 Sep 15;159(6):3000-8.

PMID:
9300725
21.

Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry.

Pleskoff O, Tréboute C, Brelot A, Heveker N, Seman M, Alizon M.

Science. 1997 Jun 20;276(5320):1874-8.

22.

Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity.

Brelot A, Heveker N, Pleskoff O, Sol N, Alizon M.

J Virol. 1997 Jun;71(6):4744-51.

Supplemental Content

Loading ...
Support Center